Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02879162
Title Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries CAN

Facility Status City State Zip Country Details
Cross Cancer Institute Edmonton Alberta T6G 1Z2 Canada Details
BCCA - Cancer Centre for the Southern Interior Kelowna British Columbia V1Y 5L3 Canada Details
BCCA - Vancouver Cancer Centre Vancouver British Columbia V5Z 4E6 Canada Details
CancerCare Manitoba Winnipeg Manitoba R3E 0V9 Canada Details
QEII Health Sciences Centre Halifax Nova Scotia B3H 1V7 Canada Details
Juravinski Cancer Centre at Hamilton Health Sciences Hamilton Ontario L8V 5C2 Canada Details
London Regional Cancer Program London Ontario N6A 5W9 Canada Details
Ottawa Hospital Research Institute Ottawa Ontario K1H 8L6 Canada Details
University Health Network Toronto Ontario M5G 2M9 Canada Details
CHUM-Centre Hospitalier de l'Universite de Montreal Montreal Quebec H2X 3E4 Canada Details
The Research Institute of the McGill University Montreal Quebec H4A 3J1 Canada Details
Allan Blair Cancer Centre Regina Saskatchewan S4T 7T1 Canada Details
Saskatoon Cancer Centre Saskatoon Saskatchewan S7N 4H4 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field